OCT 19, 2016 5:46 AM PDT

Immunotherapy Drug Doubles Survival in Head and Neck Cancer

WRITTEN BY: Xuan Pham

Head and neck cancers that are metastatic or resistant to cisplatin are notoriously aggressive. The prognosis for patients in this group is grim at less than 6 months. However, a new immunotherapy may prove to be a game-changer for these patients, as more promising results are coming to light.
 

Image credit: Pixabay.com


The drug is called nivolumab, and belongs to a class of medicines called PD-1 immune checkpoint inhibitors. Essentially this drug works by blocking a programmed death receptor in the body’s immune cells, allowing these cells to perk up longer and attack the tumor. The drug is marketed under the name Opdivo by Bristol-Myers Squibb, and is FDA-approved for the treatment of other cancer types, including melanoma, lung and kidney cancer.
 
"We don't have effective treatments for advanced head and neck cancers - these cancers are notoriously difficult to treat. So it's exciting that this phase III trial has been the first to show a significant survival benefit with an immunotherapy," said Kevin Harrington, Professor of Biological Cancer Therapies at The Institute of Cancer Research, London, and the senior study author.
 
"Once it has relapsed or spread, head and neck cancer is extremely difficult to treat, with surgery and radiotherapy often impossible. So it's very good news for patients that these interim results indicate we now have a new treatment that works, and can significantly extend life."
 


Presenting their work in both at the European Society for Medical Oncology 2016 Congress in Copenhagen, Denmark, and in print in the New England Journal of Medicine, Harrington sees much hope in nivolumab.
 
The phase III study involved 361 patients with metastatic head and neck cancer. The patients were randomized to receive three different chemotherapies, or the immunotherapy with nivolumab. At the one-year mark, the number of patients still alive with nivolumab was more than doubled that of chemotherapy (36 versus 17. Median survival was also extended in patients treated with the immunotherapy.
 
"Overall survival was significantly longer with nivolumab than with standard therapy, and nivolumab-treated patients had a risk of death that was 30 percent lower than the risk among patients assigned to standard therapy,” the authors wrote.
 


"Nivolumab was not only more effective than chemotherapy for patients with head and neck cancer but also had fewer side-effects, and has the potential to significantly extend life and increase quality of life,” Harrington added. They reported side effects were seen in about 13 percent of patients on nivolumab, whereas over 35 percent of patients on standard chemotherapy had side effects.
 
"Nivolumab could be a real game-changer for patients with advanced head and neck cancer. This trial found that it can greatly extend life among a group of patients who have no existing treatment options, without worsening quality of life,” said Harrington.

Additional sources: MNT, Institute of Cancer Research

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 04, 2020
Cancer
APR 04, 2020
Unique Cancer Mutation Hijacks Nearby Signaling Pathway
  In cancer, tyrosine kinase mutations are quite common. MET is one such example that normally binds its native lig ...
APR 21, 2020
Clinical & Molecular DX
APR 21, 2020
Skin Deep: Handheld Device Sees the Earliest Signs of Cancer
Researchers have developed a handheld device that can image structures under the skin at resolutions 100 times greater t ...
APR 23, 2020
Cancer
APR 23, 2020
Dual Inhibition from One Chemotherapy
Acute Myeloid Leukemia, or AML, is an aggressive blood cancer with a poor 5-year prognosis. The primary targets of chemo ...
APR 30, 2020
Cancer
APR 30, 2020
A New microRNA for the Cancer Fighting Toolkit
MiRNAs are small snippets of genetic information that regulate gene expression thought to be able to regulate up to 60% ...
MAY 05, 2020
Cancer
MAY 05, 2020
Can a face-aging app improve sun protection behavior?
Can a face-aging mobile app improve the skin cancer protection behavior of teenagers? A cluster-randomized clinical tria ...
MAY 13, 2020
Drug Discovery & Development
MAY 13, 2020
Approved Treatment for RET-mutant Cancers
A drug was recently approved for treating three types of RET-mutant cancers: 1) non-small cell lung cancer (NSCLC) 2) ad ...
Loading Comments...